Key points are not available for this paper at this time.
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
Edward M. Schaeffer
Sandy Srinivas
Emmanuel S. Antonarakis
Journal of the National Comprehensive Cancer Network
University of Pennsylvania
University of California, San Diego
University of California, San Francisco
Building similarity graph...
Analyzing shared references across papers
Loading...
Schaeffer et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69df28c8d5404a0bea59231c — DOI: https://doi.org/10.6004/jnccn.2021.0008